Biodegradable Cationic Lipids for Low-Toxicity RNA Nanoparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid nanoparticle carriers for RNA-based therapies face challenges in delivering RNA molecules effectively due to biological barriers such as extracellular and intracellular barriers, rapid degradation by serum ribonucleases, and high in vivo toxicity, necessitating improved delivery systems with reduced toxicity and enhanced targeting.
Innovation Solution
The development of dipeptoid-like lipids synthesized via multi-component reactions (MCRs) that form lipid nanoparticles, incorporating biodegradable ester bonds and enabling direct coupling with steroids and peptides for enhanced interaction and targeting, while maintaining flexibility in molecular structure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amino lipids are used in lipid nanoparticle carriers, then RNA delivery efficiency is improved, but in vivo toxicity increases
Solution Approach 1:
The patent modifies the chemical structure of amino lipids by incorporating biodegradable ester bonds and adjusting molecular parameters (such as chain length, saturation, and functional group composition) to reduce toxicity while preserving RNA delivery capability. This involves changing the chemical composition and structural parameters of the lipid components to achieve a balance between efficacy and safety
Solution Approach 2:
The patent develops composite lipid formulations that combine amino lipids with other lipid types (such as phospholipids, cholesterol, and PEG-lipids) in specific ratios. This multi-component approach allows the system to maintain high RNA delivery efficiency while the diverse composition reduces overall toxicity through synergistic effects and reduced reliance on high concentrations of toxic amino lipids
2Reliability
If RNA molecules are delivered to target cells, then therapeutic effect is achieved, but rapid degradation by serum ribonucleases occurs
Solution Approach 1:
The patent employs lipid nanoparticle encapsulation as a protective barrier that is prepared in advance to shield RNA molecules from serum ribonucleases. The lipid bilayer structure is designed to provide preemptive protection during circulation, preventing enzymatic degradation before the RNA reaches its target destination
Solution Approach 2:
The lipid nanoparticle acts as an intermediary carrier between the RNA molecule and the biological environment. This mediator protects the RNA from direct exposure to degradative enzymes in serum while facilitating controlled delivery to target cells, thus extending RNA stability without compromising therapeutic function
3Reliability
If nanoparticles escape endosome before lysosome formation, then RNA delivery efficiency is improved, but complexity of delivery mechanism increases
Solution Approach 1:
The patent designs lipid nanoparticles with endosome-escaping capabilities through self-service mechanisms, where the nanoparticle's inherent properties (such as pH-responsive ionizable lipids that undergo conformational changes in acidic endosomal environments) automatically facilitate escape without requiring external intervention or complex additional components. The system uses the endosome's own acidic environment to trigger the escape mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dipeptoid-like lipids reduce in vivo toxicity, enhance targeting, and improve the efficiency of RNA delivery by strengthening interactions with cargo molecules, thereby overcoming biological barriers and ensuring effective cellular uptake.
Implementation Method 1
dipeptoid-like lipids, which can be used in combination with other lipid components, such as neutral lipids, cholesterol, and polymer-bound lipids, to form lipid nanoparticles
Data Source
AI summary
The present disclosure provides compounds and the preparation methods, lipid nanoparticles, and pharmaceutical compositions thereof. The compound includes at least one structural formula (I-1) and may be provided as a pharmaceutically acceptable salt, prodrug, or isomer. The compounds of the present disclosure increase structural diversity among lipid molecules. The structure of the compounds directly provides biodegradablity. The L1a, L1b, and L1c groups in the compounds can be interchanged with the L2 group, enabling the integration of other molecules such as steroids and peptides for direct and fast screening. This interchangeability expands the functionality of the cationic lipid compounds, allowing for the direct coupling of functional molecules to the lipid compound to expand its functions. The replaceable L groups offer greater flexibility in selecting L1a, L1b, L1c, and L2.